Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings
NCT ID: NCT03033550
Last Updated: 2018-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2017-05-08
2018-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Outcome measures. The primary outcome of interest is receipt of the first dose and completion of the three-dose series of HPV vaccine within 6 month of intervention, this will be evaluated by Electronic medical review review.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Behavioral Intervention Study for Better Breast and Cervical Cancer Control for Korean American Women
NCT00857636
Giving Immunizations Through Vaccine Education
NCT01159093
Messages For Your Health: A Cancer Screening Prevention Study
NCT02376023
Implementing Personal Health Records to Promote Evidence-Based Cancer Screening
NCT02138448
Disseminating Public Health Evidence to Support State Health Department Prevention of Cancer and Other Chronic Diseases
NCT01978054
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many of the HPV-associated cancers are preventable with a series of safe and effective HPV vaccines. To date, no state has attained the 80% target vaccination rate for HPV. Despite the proven benefits and safety of HPV vaccine, usage remains suboptimal (only 38% had completed the three-dose series) and lower than other recommended adolescent vaccines.
Objective/Hypothesis: Our short term objective is to increase HPV vaccine initiation and completion rates among all age-eligible adolescent girls for whom vaccine is not contraindicated; and explore and examine acceptability of providing HPV vaccination to female youth during her adult female guardian's (AFG) cervical cancer screening appointment.
The investigators hypothesize that a combined intervention which includes (1) a motivational web-based education aimed at AFGs and youth females in their Primary Care site; and (2) text message reminders and an informational web-link on HPV vaccine and cervical cancer screening will increase HPV vaccination rates among youth females and will increase cervical cancer screening rates among their respective AFGs.
The investigators propose the following Aim:
Specific Aim: Conduct a single-arm proof of concept, open trial clinical study investigating the feasibility and efficacy of integrating primary and secondary prevention model for HPV and cervical cancer: a mobile educational and automated electronic interactive messaging intervention that will remind AFG and youth females of scheduled and missed second and third HPV vaccination appointments, and deliver brief text and video educational messaging on HPV, HPV vaccine, and cervical cancer screening.
Study Design: The investigators will conduct an open feasibility proof-of-concept trial using a single experimental group with all subjects receiving the behavioral intervention being studied.
Outcome measures. The primary outcome of interest is receipt of the first dose and completion of the three-dose series of HPV vaccine within 6 month of intervention, this will be evaluated by Electronic medical review review.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
single
single arm- behavioral educational intervention of a brief negotiated mobile application
brief negotiated mobile application
The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
brief negotiated mobile application
The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AFG consent to have cervical cancer screening status checked in Electronic Medical Record.
* AFG has a daughter between the ages of 11 to 17 who receive primary care at either
* Family Medicine or Pediatric and Adolescent primary care clinic at Boston Medical Center.
* AFG consent to have daughter's HPV vaccination status checked in Electronic Medical Record.
* AFG's daughter has neither initiated the HPV vaccine nor completed the three vaccine series
* AFG and daughter have the ability to read and write in English.
* AFG and daughter each have a cell phone with text messages capabilities.
Exclusion Criteria
* AFG being seen for a sick visit.
* AFG has an adolescent daughter who is pregnant or is a mother.
* AFG has a daughter who has completed the three dose HPV vaccine series.
* AFG, in the opinion of the clinical staff, is cognitively impaired and unable to give informed consent and may not participate.
9 Years
17 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Natalie Pierre-Joseph
Assistant Professor of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natalie Joseph, MD MPH
Role: PRINCIPAL_INVESTIGATOR
Boston Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boston Medical Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-34457
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.